The relentless march of time is an inescapable fact, but its effects on our overall well-being are profound and intricate. Referred to by some experts as the “master disease”, aging is more than merely growing older. It represents the functional decline of a living organism over time. This article probes into the multifaceted nature of biological aging, its repercussions, and the innovative ways in which science is demystifying and even countering its challenges. [Read more…]
Restoration of Whole-Person Health: Re-envisioning Global Access
Scientists increasingly agree that the convergence of advanced longevity technologies and regenerative medicines offers great promise for chronic disease prevention and optimal health throughout the individual’s lifespan. Thought leaders in these fields lament that in the rapidly evolving medical landscape, the journey from groundbreaking research to practical application is often fraught with challenges. HEALinc, a future health research and development (R&D) organization founded by Dr. Desirée Cox, is dedicated to overcoming the “Valley of Death” hurdle and ensuring that life-changing, longevity-enhancing therapies reach those who need them most. [Read more…]
I Peace manufactures 100 lines of GMP iPS Cells cumulatively
Proof of customer recognition of its quality and mass manufacturing capability
Palo Alto, CA, January 7, 2025 — Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the number of GMP-grade iPS cells manufactured has reached 100 lines. This achievement solidifies I Peace as a true leader in the realm of iPS cell manufacturers, equipped with abundant experience in manufacturing GMP-grade iPS cells in compliance with global regulations. [Read more…]
Tolerance Bio Announces Scientific Advisory Board and $20.2M Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases
World-class leaders in the thymus, immunology, oncology, cell therapy, and drug development will inform and support the Company’s efforts to preserve, restore, and manipulate the thymus to address immune diseases
Pacific 8 Ventures joined the seed round syndicate led by Columbus Venture Partners, with participation by Criteria Bio Ventures, Sessa Capital, BioAdvance, and Ben Franklin Technology Partners
PHILADELPHIA, December 19, 2024 –Tolerance Bio, Inc., a biopharma company pioneering innovative approaches to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, today announced the formation of its Scientific Advisory Board (SAB) and the completion of its oversubscribed $20.2M seed financing round. [Read more…]
What Is the Future of the Stem Cell Market in 2025?
Stem cell therapy continues to rally worldwide recognition as governments fund research and expand access. This once-controversial therapy is fast becoming one of medicine’s most exciting technologies. From FDA-approved therapies to in-house, physician-initiated autologous techniques, stem cell technology continues to evolve. 2025 promises to be an exciting year for the stem cell market.
Here’s everything you need to know about the future of this revolutionary therapy. [Read more…]
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 200
- Next Page »